A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 18 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2019 Planned End Date changed from 26 Jul 2019 to 11 Oct 2019.